These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 15794865

  • 1. CD52 expression in Waldenstrom's macroglobulinemia: implications for alemtuzumab therapy and response assessment.
    Owen RG, Hillmen P, Rawstron AC.
    Clin Lymphoma; 2005 Mar; 5(4):278-81. PubMed ID: 15794865
    [Abstract] [Full Text] [Related]

  • 2. CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders.
    Santos DD, Hatjiharissi E, Tournilhac O, Chemaly MZ, Leleu X, Xu L, Patterson C, Branagan AR, Manning RJ, Ho AW, Hunter ZR, Dimmock EA, Kutok JL, Churchill WH, Castells MC, Tai YT, Anderson KC, Treon SP.
    Clin Lymphoma Myeloma; 2006 May; 6(6):478-83. PubMed ID: 16796779
    [Abstract] [Full Text] [Related]

  • 3. CD52 expression in T-cell large granular lymphocyte leukemia--implications for treatment with alemtuzumab.
    Osuji N, Del Giudice I, Matutes E, Morilla A, Owusu-Ankomah K, Morilla R, Dunlop A, Catovksy D.
    Leuk Lymphoma; 2005 May; 46(5):723-7. PubMed ID: 16019510
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab.
    Treon SP, Soumerai JD, Hunter ZR, Patterson CJ, Ioakimidis L, Kahl B, Boxer M.
    Blood; 2011 Jul 14; 118(2):276-81. PubMed ID: 21566092
    [Abstract] [Full Text] [Related]

  • 8. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies.
    Albitar M, Do KA, Johnson MM, Giles FJ, Jilani I, O'Brien S, Cortes J, Thomas D, Rassenti LZ, Kipps TJ, Kantarjian HM, Keating M.
    Cancer; 2004 Sep 01; 101(5):999-1008. PubMed ID: 15329909
    [Abstract] [Full Text] [Related]

  • 9. CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice.
    Carlo-Stella C, Guidetti A, Di Nicola M, Longoni P, Cleris L, Lavazza C, Milanesi M, Milani R, Carrabba M, Farina L, Formelli F, Gianni AM, Corradini P.
    Exp Hematol; 2006 Jun 01; 34(6):721-7. PubMed ID: 16728276
    [Abstract] [Full Text] [Related]

  • 10. Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy.
    Jiang L, Yuan CM, Hubacheck J, Janik JE, Wilson W, Morris JC, Jasper GA, Stetler-Stevenson M.
    Br J Haematol; 2009 Apr 01; 145(2):173-9. PubMed ID: 19236377
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and tolerability of alemtuzumab (CAMPATH-1H) in the salvage treatment of B-cell chronic lymphocytic leukemia--change of regimen needed?
    Rieger K, Von Grünhagen U, Fietz T, Thiel E, Knauf W.
    Leuk Lymphoma; 2004 Feb 01; 45(2):345-9. PubMed ID: 15101722
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Emergence of CD52-, glycosylphosphatidylinositol-anchor-deficient lymphocytes in rheumatoid arthritis patients following Campath-1H treatment.
    Brett SJ, Baxter G, Cooper H, Rowan W, Regan T, Tite J, Rapson N.
    Int Immunol; 1996 Mar 01; 8(3):325-34. PubMed ID: 8671618
    [Abstract] [Full Text] [Related]

  • 14. CD52 expression patterns in myeloma and the applicability of alemtuzumab therapy.
    Rawstron AC, Laycock-Brown G, Hale G, Davies FE, Morgan GJ, Child JA, Hillmen P, Owen RG.
    Haematologica; 2006 Nov 01; 91(11):1577-8. PubMed ID: 17043027
    [Abstract] [Full Text] [Related]

  • 15. Clonal CD8+ and CD52- T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52).
    Osterborg A, Werner A, Halapi E, Lundin J, Harmenberg U, Wigzell H, Mellstedt H.
    Eur J Haematol; 1997 Jan 01; 58(1):5-13. PubMed ID: 9020367
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism.
    Mone AP, Cheney C, Banks AL, Tridandapani S, Mehter N, Guster S, Lin T, Eisenbeis CF, Young DC, Byrd JC.
    Leukemia; 2006 Feb 01; 20(2):272-9. PubMed ID: 16341049
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.